S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celgene Receives Positive CHMP Opinion to Extend REVLIMID® (Lenalidomide) for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant|
|Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation|
|Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis|
|Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress|
|UPDATE: Updates, advisories and surprises (2015/1/12)|
|Celgene Upbeat About Revlimid Sales But Warns on Currency Effects (2015/1/12)|
|Oral OTEZLA® (apremilast) Approved by the European Commission for the Treatment of both Patients with Psoriasis and Psoriatic Arthritis|
|Data from More Than 160 Abstracts Highlighting Celgene Therapies to Be Presented at American Society of Hematology Annual Meeting (ASH)|
|Celgene Corporation Announces 2015 and Long-Term Financial Outlook and Preliminary 2014 Results|
|Celgene Reports Third Quarter 2014 Operating and Financial Results|
Click above to view more mutual fund data and stats for celg - Celgene Corp.